Amicus Therapeutics Inc (FOLD)

04:04 AM

Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200 - Seeking Alpha

04:04 AM

11:49 AM

FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales - TradingView

11:49 AM

10:30 AM

Envestnet Asset Management Inc. Has $1.52 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

10:30 AM

08:23 AM

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2025 Earnings Call Transcript - Insider Monkey

08:23 AM

07:25 AM

What are analysts’ price targets for Amicus Therapeutics Inc. in the next 12 monthsDaily Trading Picks With High Returns - jammulinksnews.com

07:25 AM

06:40 AM

Y Intercept Hong Kong Ltd Trims Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

06:40 AM

04:29 AM

Universal Beteiligungs und Servicegesellschaft mbH Makes New $1.74 Million Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

04:29 AM

02:04 AM

Amicus Therapeutics: Q2 Earnings Snapshot - Greenwich Time

02:04 AM

12:20 PM

Amicus Therapeutics 2025 Q2 Earnings Misses Targets as Net Income Drops 55.6% - AInvest

12:20 PM

Jul 31, 2025

Bank of America Securities Remains Bullish on Amicus Therapeutics (FOLD) With a $13 PT - Insider Monkey

Jul 31, 2025

Jul 31, 2025

Amicus reiterates $1B sales target for Galafold and Pombiliti/Opfolda by 2028 amid global expansion and Phase III pipeline progress - MSN

Jul 31, 2025

Jul 31, 2025

Amicus Therapeutics Q2 2025: Unraveling Contradictions in Revenue Impact, Trial Designs, and Market Dynamics - AInvest

Jul 31, 2025

Jul 31, 2025

Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates - GlobeNewswire

Jul 31, 2025

Jul 31, 2025

Amicus (FOLD) Gets Japan Approval for Pombiliti + Opfolda - MSN

Jul 31, 2025

Jul 31, 2025

Earnings call transcript: Amicus Therapeutics beats revenue forecast in Q2 2025 - Investing.com

Jul 31, 2025

Jul 31, 2025

Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates - Yahoo.co

Jul 31, 2025

Jul 31, 2025

Is Amicus Therapeutics (NASDAQ:FOLD) A Risky Investment? - simplywall.st

Jul 31, 2025

Jul 31, 2025

Amicus Therapeutics Q2 rev. $154.7mln, up 18% YoY, reiterates 2025 guidance. - AInvest

Jul 31, 2025

Jul 31, 2025

Amicus Therapeutics Q2 2025 revenue up 18% YoY to $154.7mln. - AInvest

Jul 31, 2025

Jul 31, 2025

Amicus Therapeutics Q2 2025 Financial Results and Corporate Updates - TradingView

Jul 31, 2025

Jul 31, 2025

Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates - GlobeNewswire Inc.

Jul 31, 2025

Jul 31, 2025

10 Best Strong Buy Stocks to Buy Under $10 - Insider Monkey

Jul 31, 2025

Jul 31, 2025

Pompe Disease Market Size 2034: EMA, PDMA, FDA Approval, - openPR.com

Jul 31, 2025

Jul 30, 2025

Victory Capital Management Inc. Has $2.10 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Jul 30, 2025

Jul 29, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Legato Capital Management LLC - MarketBeat

Jul 29, 2025

Jul 29, 2025

Price Consolidation Hints at Upcoming Move in Amicus Therapeutics Inc.Community Shared Smart Money Signals Show Movement - metal.it

Jul 29, 2025

Jul 29, 2025

Amicus Therapeutics FOLD 2025Q2 Earnings Preview Upside Potential with Strong Patient Demand Projection - AInvest

Jul 29, 2025

Jul 28, 2025

When is Amicus Therapeutics Inc. stock expected to show significant growthDaily Trading Guidance To Watch Now - jammulinksnews.com

Jul 28, 2025

Jul 28, 2025

What are Amicus Therapeutics Inc. company’s key revenue driversRapid wealth multiplication - jammulinksnews.com

Jul 28, 2025

Jul 28, 2025

Is Amicus Therapeutics Inc. stock overvalued or undervaluedAchieve breakthrough performance in the market - jammulinksnews.com

Jul 28, 2025

Jul 28, 2025

What is the dividend policy of Amicus Therapeutics Inc. stockAchieve fast wealth growth with smart picks - jammulinksnews.com

Jul 28, 2025

Jul 27, 2025

Amicus Therapeutics (FOLD) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Jul 27, 2025

Jul 27, 2025

Why is Amicus Therapeutics Inc. stock attracting strong analyst attentionDiscover hidden gems in the stock market - jammulinksnews.com

Jul 27, 2025

Jul 27, 2025

Is it the right time to buy Amicus Therapeutics Inc. stockUnlock expert stock analysis and alerts - jammulinksnews.com

Jul 27, 2025

Jul 26, 2025

What makes Amicus Therapeutics Inc. stock price move sharplyROI Driven Alerts - metal.it

Jul 26, 2025

Jul 24, 2025

Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion - Insider Monkey

Jul 24, 2025

Jul 24, 2025

Amicus Therapeutics Inc. Stock Analysis and ForecastFree AI-Backed Trading Signals - PrintWeekIndia

Jul 24, 2025

Jul 24, 2025

How Amicus Therapeutics Inc. stock reacts to Fed policy changesFree Investment Portfolio Suggestions - jammulinksnews.com

Jul 24, 2025

Jul 24, 2025

Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

Jul 24, 2025

Jul 23, 2025

What drives Amicus Therapeutics Inc. stock priceExceptional profit margins - Autocar Professional

Jul 23, 2025

Jul 23, 2025

Edgestream Partners L.P. Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Jul 23, 2025

Jul 22, 2025

What analysts say about Amicus Therapeutics Inc. stockSkyrocketing investment returns - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Published on: 2025-07-23 00:04:03 - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Is Amicus Therapeutics Inc. a good long term investmentFree High-Return Strategy Alerts - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 - GlobeNewswire

Jul 22, 2025